SLC5A2 and Alport syndrome: In a preclinical study done by Zhu et al., experiments in mice suggested that triple blockade of renin-angiotensin system (RAS), sodium glucose transporter 2 (SGLT2), and mineralocorticoid receptor (MR) may substantially improve renal outcomes in Alport syndrome and possibly other progressive chronic kidney diseases because of synergistic effects on the glomerular and tubulointerstitial compartments [9].